Evidence map›Paper›PMID 30403848›Full record

ArticleACS chemical biology2018

Model Colibactins Exhibit Human Cell Genotoxicity in the Absence of Host Bacteria.

Emilee E Shine, Mengzhao Xue, Jaymin R Patel, Alan R Healy, Yulia V Surovtseva, Seth B Herzon, Jason M Crawford

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Insights into the acquisition of theMicrobial genomics · 2021
    Article
  12. Structure and bioactivity of colibactin.Bioorganic & medicinal chemistry letters · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Emilee E ShineDepartment of Microbial Pathogenesis , Yale School of Medicine , New Haven , Connecticut 06536 , United States.ORCID 0000-0002-1290-2496
Mengzhao XueDepartment of Chemistry , Yale University , New Haven , Connecticut 06520 , United States.
Jaymin R PatelChemical Biology Institute , Yale University , West Haven , Connecticut 06516 , United States.ORCID 0000-0002-4380-4805
Alan R HealyChemical Biology Institute , Yale University , West Haven , Connecticut 06516 , United States.ORCID 0000-0002-1231-8353
Yulia V SurovtsevaYale Center for Molecular Discovery , West Haven , Connecticut 06516 , United States.
Seth B HerzonDepartment of Chemistry , Yale University , New Haven , Connecticut 06520 , United States.ORCID 0000-0001-5940-9853
Jason M CrawfordDepartment of Microbial Pathogenesis , Yale School of Medicine , New Haven , Connecticut 06536 , United States.ORCID 0000-0002-7583-1242
Yale University · US

Funding

Predoc Training at the Interface Chemistry and BiologyT32GM067543 · NIGMS · YALE UNIVERSITY · PI CRAWFORD, JASON MICHAEL · 2003 to 2022
$7.4M
Structural and functional studies of colibactinR01CA215553 · NCI · YALE UNIVERSITY · PI Seth B. Herzon, Christian Jobin · 2018 to 2026
$5.5M
Cryptic gut bacterial metabolites that regulate colorectal cancer formationDP2CA186575 · NCI · YALE UNIVERSITY · PI CRAWFORD, JASON MICHAEL · 2013 to 2013
$2.5M
Synthesis and Study of Complex Antiproliferative and Antimalarial Natural ProductsR01GM110506 · NIGMS · YALE UNIVERSITY · PI HERZON, SETH B. · 2015 to 2018
$1.2M
EPA EP-W-17-011NCI NIH HHS DP2 CA186575NCI NIH HHS R01 CA215553NIGMS NIH HHS R01 GM110506NIGMS NIH HHS T32 GM067543
6 · The paper itself

Abstract

Colibactins are genotoxic secondary metabolites produced in select Enterobacteriaceae, which induce downstream DNA double-strand breaks (DSBs) in human cell lines and are thought to promote the formation of colorectal tumors. Although key structural and functional features of colibactins have been elucidated, the full molecular mechanisms regulating these phenotypes remain unknown. Here, we demonstrate that free model colibactins induce DSBs in human cell cultures and do not require delivery by host bacteria. Through domain-targeted editing, we demonstrate that a subset of native colibactins generated from observed module skipping in the nonribosomal peptide synthetase-polyketide synthase (NRPS-PKS) biosynthetic assembly line share DNA alkylation phenotypes with the model colibactins in vitro. However, module skipping eliminates the strong DNA interstrand cross-links formed by the wild-type pathway in cell culture. This product diversification during the modular NRPS-PKS biosynthesis produces a family of metabolites with varying observed mechanisms of action (DNA alkylation versus cross-linking) in cell culture. The presence of membranes separating human cells from model colibactins attenuated genotoxicity, suggesting that membrane diffusion limits colibactin activity and could account for the reported bacterium-human cell-to-cell contact phenotype. Additionally, extracellular supplementation of the colibactin resistance protein ClbS was able to intercept colibactins in an Escherichia coli-human cell transient infection model. Our studies demonstrate that free model colibactins recapitulate cellular phenotypes associated with module-skipped products in the native colibactin pathway and define specific protein domains that are required for efficient DNA interstrand cross-linking in the native pathway.

Indexed as

AlkylationCell Line, TumorCross-Linking ReagentsDNADNA Breaks, Double-StrandedEscherichia coliHumansMutagensPeptidesPolyketidescolibactinCross-Linking ReagentsDNAMutagensPeptidesPolyketides

Identifiers

PMID30403848
PMCPMC7001666
OpenAlexW2893901589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.